| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Recilisib sodium (formerly known as ON 01210.Na; ON-01210; ON01210; EX-RAD), the soiumd salt of recilisib, is a radioprotectant that is being studies in phase 1 clinical trials by Onconova Therapeutics for the treatment of acute radiation syndrome. It is able to mitigate radiation damage through activation of the AKT pathway. Recilisib modifies cell cycle distribution patterns in cancer cells subjected to radiation therapy, and it has been identified as a potential candidate for radiation protection studies. It appears that Recilisib radioprotective mechanisms involve prevention of p53-dependent and independent radiation-induced apoptosis.
| ln Vitro |
Recilisib Sodium (up to 50 μM) has a typical cell cycle distribution, with a modest decrease in S phase cell counts at that concentration. Recilisib Sodium (100 μM) does not cause cell death when exposed continuously. Treatment with Recilisib Sodium does not prevent human myeloid cells from forming colonies. Recilisib Sodium protected human bone marrow cells at all three IR dosages in a dose-dependent manner. In HFL cells, retilisib sodium stimulates the phosphorylation of AKT and GSK3α/β. In response to radiation exposure, Recilisib Sodium raises PI3K activity in HFL-1 cells and mice bone marrow cells. Combining radiation therapy with Recilisib sodium administration modifies the MAPK signaling pathway [1].
|
|---|---|
| ln Vivo |
The recovery and differentiation rate of primary bone marrow myeloid progenitor cells in mice is markedly enhanced by Recilisib Sodium (500 mg/kg). Mice CFU counts were decreased when Recilisib Sodium was combined with radiation, although mice treated with Recilisib Sodium continuously maintained their capacity to form differentiated colonies. Exposure to radiation never totally depletes the progenitor cell population in mice given Recilisib Sodium [1].
|
| References |
| Molecular Formula |
C16H12CLNAO4S
|
|---|---|
| Molecular Weight |
358.7678
|
| Exact Mass |
358.004
|
| CAS # |
922139-31-9
|
| Related CAS # |
Recilisib;334969-03-8
|
| PubChem CID |
23668369
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.37
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
499
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(/C1C=CC(C(=O)O)=CC=1)=C\S(=O)(=O)CC1C=CC(Cl)=CC=1.[Na]
|
| InChi Key |
PRFBWBYKWZVQJF-RRABGKBLSA-M
|
| InChi Code |
InChI=1S/C16H13ClO4S.Na/c17-15-7-3-13(4-8-15)11-22(20,21)10-9-12-1-5-14(6-2-12)16(18)19;/h1-10H,11H2,(H,18,19);/q;+1/p-1/b10-9+;
|
| Chemical Name |
sodium;4-[(E)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]benzoate
|
| Synonyms |
Recilisib sodium; ON 01210.Na; Ex-RAD; ON-01210; ON01210; ON01210;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7873 mL | 13.9365 mL | 27.8730 mL | |
| 5 mM | 0.5575 mL | 2.7873 mL | 5.5746 mL | |
| 10 mM | 0.2787 mL | 1.3937 mL | 2.7873 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
